0 avis
A Comparative Profitability Analysis of Transcatheter versus Surgical Aortic Valve Replacement in a High-Volume French Hospital
Archive ouverte
Edité par CCSD ; SpringerOpen -
International audience. BACKGROUND: Current scientific guidelines have extended the indication for transcatheter aortic valve replacement (TAVR) to patients who present an intermediate risk for surgery and have been so far considered for conventional surgery. We previously demonstrated that the TAVR procedure generated profits despite elevated costs, but comparison with surgery has not been performed. The objective of this study was to assess the profitability of the TAVR procedure compared with conventional surgery in a high-volume French hospital. Consecutive patients eligible for transfemoral TAVR or surgical aortic valve replacement (SAVR) were included retrospectively in this single-centre study between September 2014 and December 2015. The primary endpoint was the profitability of each procedure (defined as the ratio between the profit and total revenues), calculated for each patient. Secondary composite endpoints included major adverse events in the 30\,days following procedure and breakdown of costs. RESULTS: Two hundred and thirty-eight patients were included in the TAVR group and 341 in the SAVR group. TAVR patients presented higher operative risk scores and more comorbidities. Compared with SAVR, TAVR was associated with higher profits (\texteuro 2732\,±\,1768 per patient vs. \texteuro 2177\,±\,2437 per patient, P\,<\,0.001) but also higher costs (\texteuro 27,778\,±\,4961 vs. \texteuro 17,813\,±\,6071, P\,<\,0.001) resulting in lower profitability (9.3\,±\,5.7% vs. 11.7\,±\,10.1%, P\,<\,0.001). The price of the bioprosthesis represented 70% of the TAVR total cost. CONCLUSIONS: TAVR performed in carefully selected patients was associated with higher profits than SAVR, but also higher costs resulting in lower profitability.
Consulter en ligne
Suggestions
Du même auteur
